114 related articles for article (PubMed ID: 34711369)
1. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys.
Zamora V; Garin O; Pardo Y; Pont À; Gutiérrez C; Cabrera P; Gómez-Veiga F; Pijoan JI; Litwin MS; Ferrer M;
Value Health; 2021 Nov; 24(11):1676-1685. PubMed ID: 34711369
[TBL] [Abstract][Full Text] [Related]
2. Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).
Bremner KE; Mitsakakis N; Wilson L; Krahn MD
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):47-56. PubMed ID: 24126796
[TBL] [Abstract][Full Text] [Related]
3. Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS).
Avila M; Pardo Y; Castells M; Ferrer F; Boladeras A; Pera J; Prada PJ; Guix B; de Paula B; Hernandez H; Pont A; Alonso J; Garin O; Bremner K; Krahn M; Ferrer M;
Qual Life Res; 2014 Nov; 23(9):2481-7. PubMed ID: 24789667
[TBL] [Abstract][Full Text] [Related]
4. Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments.
Schmidt S; Garin O; Pardo Y; Valderas JM; Alonso J; Rebollo P; Rajmil L; Garcia-Forero C; Ferrer M;
Qual Life Res; 2014 Oct; 23(8):2169-81. PubMed ID: 24748557
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a utility weighting function for the patient-oriented prostate utility scale (PORPUS).
Tomlinson G; Bremner KE; Ritvo P; Naglie G; Krahn MD
Med Decis Making; 2012; 32(1):11-30. PubMed ID: 21653804
[TBL] [Abstract][Full Text] [Related]
6. Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
Khairnar R; Pugh SL; Sandler HM; Lee WR; Villalonga Olives E; Mullins CD; Palumbo FB; Bruner DW; Shaya FT; Bentzen SM; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Albert M; Currey AD; Pisansky TM; Chen Y; Horwitz EM; DeNittis AS; Feng FY; Mishra MV
PLoS One; 2021; 16(4):e0249123. PubMed ID: 33852571
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
[TBL] [Abstract][Full Text] [Related]
8. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.
Krahn MD; Bremner KE; Alibhai SM; Ni A; Tomlinson G; Laporte A; Naglie G
Qual Life Res; 2013 Dec; 22(10):2951-62. PubMed ID: 23564620
[TBL] [Abstract][Full Text] [Related]
9. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
Sibert NT; Dieng S; Oesterle A; Feick G; Carl G; Steiner T; Minner J; Roghmann F; Kaftan B; Zengerling F; Hinkel A; Beyer B; Heidenreich A; Harke N; Brehmer B; Pfitzenmaier J; Fichtner J; Neisius A; Hammerer P; Wesselmann S; Kowalski C
World J Urol; 2021 Jan; 39(1):11-25. PubMed ID: 31552467
[TBL] [Abstract][Full Text] [Related]
10. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
Einstein DJ; Patil D; Chipman J; Regan MM; Davis K; Crociani CM; Wagner AA; Sanda MG; Chang P
Urology; 2019 May; 127():53-60. PubMed ID: 30790648
[TBL] [Abstract][Full Text] [Related]
11. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy.
Krahn M; Ritvo P; Irvine J; Tomlinson G; Bremner KE; Bezjak A; Trachtenberg J; Naglie G
Med Care; 2003 Jan; 41(1):153-64. PubMed ID: 12544552
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer.
Bulamu NB; Mpundu-Kaambwa C; O'Callaghan M; Kaambwa B
BMC Cancer; 2023 Apr; 23(1):297. PubMed ID: 37005587
[TBL] [Abstract][Full Text] [Related]
13. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
Szymanski KM; Wei JT; Dunn RL; Sanda MG
Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
[TBL] [Abstract][Full Text] [Related]
15. Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.
Anota A; Mariet AS; Maingon P; Joly F; Bosset JF; Guizard AV; Bittard H; Velten M; Mercier M
Health Qual Life Outcomes; 2016 Dec; 14(1):168. PubMed ID: 27923377
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of utility index of quality of life (QOL) in prostate cancer patients: comparison of QOL utility index EuroQol-5D (EQ-5D) and visual analogue scale (VAS) with health-related QOL questionnaires SF-36 and EPIC].
Akakura K; Matsuzaki K; Kobayashi T; Kitoh H; Mizoguchi K; Tomikawa G; Takura T; Kawabuchi K
Nihon Hinyokika Gakkai Zasshi; 2011 Jan; 102(1):9-13. PubMed ID: 21520631
[TBL] [Abstract][Full Text] [Related]
18. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
[TBL] [Abstract][Full Text] [Related]
19. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID; Crociani C; McLaughlin WP; Mantz CA; Finkelstein SE; Suy S; Collins SP; Garin O; Ferrer M; Hamstra DA; Spratt DE
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):770-777. PubMed ID: 27663760
[TBL] [Abstract][Full Text] [Related]
20. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.
Khairnar R; DeMora L; Sandler HM; Lee WR; Villalonga-Olives E; Mullins CD; Palumbo FB; Bruner DW; Shaya FT; Bentzen SM; Shah AB; Malone S; Michalski JM; Dayes IS; Seaward SA; Albert M; Currey AD; Pisansky TM; Chen Y; Horwitz EM; DeNittis AS; Feng F; Mishra MV
JCO Clin Cancer Inform; 2022 Jun; 6():e2100188. PubMed ID: 35776901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
